News

In the phase I/II study, PA-457 was administered as a single oral dose to HIV-infected patients who were not on other therapy, in order to determine the pharmacokinetics

The agreements focus on the cell-based validation of collections of candidate genes previously identified by Schering AG as possible therapeutic drug targets. Cenix will apply its industry-leading expertise

SOT-375, known as Eligard in the US, is an injectable formulation of leuprolide acetate designed to deliver 3.75mg of the drug substance at a controlled rate over 30

The service, called esymbio, aims to create an infrastructure that will foster collaboration between biotechnology companies, investors and public bodies to drive the development of the region’s life

This favorable review from Japan’s Ministry of Health, Labour and Welfare (MHLW) follows a committee review meeting and will form the basis on which the Japanese government will

Six of the 17 children who were fully evaluable at the time of the conference were reported to have demonstrated either stable disease or a partial response to

Published in the April 1, 2005 issue of CANCER, the new analysis of data from the prostate cancer prevention trial (PCPT) indicates that any possible increase in the

The clinical trial results, including pharmacokinetic data and updated visual acuity outcomes, came from a multi-center open-label US phase II clinical trial with Evizon (squalamine lactate) for the

In 2004, BCY announced the results from a phase II clinical study which led to the agreement with Align. The agreement provides for the continued development of DCF